Venture-Backed Startups

Cellular Intelligence develops cell therapy treatments, specifically acquiring STEM-PD, a Phase 2-ready therapy for Parkinson's disease. The company focuses on cell fate engineering to design biological solutions for neurological diseases.

5 investors

Cellular Logistics develops CFX, a therapeutic biomaterial made with induced pluripotent stem cell technology that can be locally administered to prevent the pathological changes leading to heart failure after an acute injury such as myocardial infarction. Combined with therapeutic stem cells, it aims to remuscularize scarred myocardium to restore heart function in chronic heart failure.

0 investors

0 investors

Cellular Origins provides automated cell therapy manufacturing solutions through its Constellation platform, which integrates robotics and digital management to enable GMP-compliant scaling of cell therapies with minimal process modification.

3 investors

Cellumed is a South Korean biotech company focused on musculoskeletal medical devices and biological products. It also develops and supplies growth factors and production enzymes used for RNA vaccines and therapeutics.

1 investor

Cellva develops natural coffee-fruit ingredients and microencapsulation formats for food and beverage brands, providing chocolate and caramel flavor, color, and functionality with traceable Brazilian origin. It sources high-value bioactives from the Amazon and produces industrial-grade ingredients for brands seeking cleaner labels and faster product innovation.

1 investor

CellVax Therapeutics is a clinical-stage company developing personalized cell-based cancer immunotherapy that converts a patient's own tumor cells into antigen-presenting "Tumor Presenting Cells" to trigger a multi-neoantigen immune response. Its lead product, FK-PC101, targets high-risk prostate cancer patients after prostatectomy, with a platform intended to extend to other solid tumors.

0 investors

cellvie develops Therapeutic Mitochondria Transplantation, a technique that augments or replaces failing mitochondria to restore cellular energy metabolism, with initial applications in ischemia-reperfusion injury (starting with kidney transplantation) and in mitochondria-enabled gene therapy for the genetic skin disease Epidermolysis Bullosa. Its therapies target intractable human conditions including organ transplant injury, degenerative aging processes, and rare genetic diseases.

2 investors

Cellview develops the WRI-1, a widefield non-mydriatic retinal imaging device that captures up to 133° in a single image and auto-stitches up to 200° for retinal periphery screening. The system is designed for eye care professionals to image patients including those with small pupils, cataracts, or other media opacities.

1 investor

CellVoyant is an AI-first company that develops predictive analytics and optimization tools for cell-based therapeutic development, helping researchers accelerate process development and reduce costs through label-free imaging analysis and data-driven process optimization.

5 investors

CellX Biosolutions develops a biological method that uses bacteria to break down PFAS ("forever chemicals"), positioned as an alternative to conventional disposal methods. The company operates in the environmental cleantech and biotech space.

2 investors

CellX offers a self-service operations management platform that automates repetitive tasks such as 24/7 order intake, multi-channel order and message handling, order status tracking, and after-sales ticket workflows. It targets e-commerce teams, content agencies, and traditional enterprises seeking to reduce manual order processing and unify data across platforms.

1 investor

Celmatix Therapeutics developed a discovery portfolio focused on women's health, including therapeutic programs for infertility, endometriosis, and ovarian aging. The company's pipeline included an oral FSH receptor agonist, a JNK inhibitor, and AMH-targeting antibodies.

1 investor

Celo is a blockchain network designed for stablecoin payments and global financial transactions, positioned as a Layer 2 solution built on Ethereum's ecosystem. It supports low-cost transactions, including gas payments with ERC20 tokens, and enables development of AI agents with real-world utility.

5 investors

Celo Core Co. is the engineering and ecosystem team behind the Celo network, building core products, tools, and infrastructure for programmable rails in global finance rooted in Ethereum. The company focuses on ecosystem development, partnerships, and community growth to create a regenerative digital economy.

1 investor

Celona provides a turnkey wireless solution for enterprise customers with Series C funding exceeding $135M to support global expansion.

6 investors

Celonis provides an enterprise AI platform that combines process data, business knowledge, and intelligence to give organizations operational clarity for AI deployment, supply chain optimization, IT modernization, and process excellence across industries.

8 investors

Celoxica provides ultra-low latency trading technology and managed services across market data, risk management, and order execution for systematic trading firms, using an FPGA-based platform with feed handlers, execution gateways, and a risk/DMA product (MAG). It serves buy-side and sell-side clients including hedge funds, quantitative traders, banks, and brokers, with colocated deployments at major global exchanges.</parameter> <parameter name="sector_codes">["fintech", "hardware", "data_infra"]

3 investors

0 investors

0 investors

Celsia offers software that helps companies comply with EU sustainability reporting requirements, including the CSRD/ESRS, the EU taxonomy, and the SFDR. Its tools support double materiality assessments, data collection, taxonomy scoring, and compliant report generation for corporates and investment funds. The company is now part of ISS-Corporate.

1 investor

CELSIUS makes energy drinks marketed for an active lifestyle, formulated without artificial preservatives, aspartame, or high fructose corn syrup. The company positions its beverages, when combined with exercise, as supporting metabolism and fat burning for fitness-focused and everyday consumers.

2 investors

Combines single-cell RNA analysis technology from the Broad Institute with AI/ML models and large-scale clinical sample collection for novel drug discovery and precision medicine. Acquired by AbbVie Inc. in June 2024.

2 investors

Celsus is an AI platform for analyzing medical images, detecting pathologies in mammography, fluorography, and CT scans of the chest and brain. Its diagnostic tools are used in radiology departments to support clinical practice and improve cancer detection.

2 investors